Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research (Formerly Faculty of Pharmacy), Jamia Hamdard, New Delhi 110062, India.
Cancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR), Canal Road, Jammu 180001, India.
Bioorg Chem. 2018 Apr;77:106-124. doi: 10.1016/j.bioorg.2018.01.007. Epub 2018 Jan 11.
Depravity of malaria in terms of morbidity and mortality in human beings makes it a major health issue in tropical and subtropical areas of the globe. Drug counterfeiting and non-adherence to the treatment regimen have significantly contributed to development and spread of multidrug resistance that has highlighted the need for development of novel and more efficient antimalarial drugs. Complexity associated with cancer disease and prevalence of diversified cell populations vindicates highly specific treatment options for treatment of cancer. Resistance to these anticancer agents has posed a great hindrance in successful treatment of cancer. Pondering this ongoing situation, it was speculated to develop novel compounds targeting malaria and cancer. Moving on the same aisle, we synthesized pyrazole acrylic acid based oxadiazole and amide derivatives using multi-step reaction pathways (6a-x; 6a'-h'). Schizont maturation inhibition assay was employed to determine antimalarial potential. Compound 6v emerged as the most potent antimalarial agent targeting falcipain-2 enzyme. Anticancer activity was done using sulforhodamine B assay. Compounds 6b' and 6g' demonstrated promising results against all the tested cell lines. Further, Microscopic view clearly indicated formation of apoptotic bodies, chromatin condensation, shrinkage of cells and bleb formation. Validation of the results was achieved using molecular docking studies. From the obtained results, it was observed that cyclization (oxadiazole) favored antimalarial activity while non-cyclized compounds (amides) emerged as better anticancer agents.
疟疾在人类中的发病率和死亡率方面的严重性使其成为全球热带和亚热带地区的主要健康问题。假药和不遵守治疗方案极大地促成了多药耐药性的发展和传播,这凸显了开发新型、更有效的抗疟药物的必要性。癌症疾病的复杂性和多样化细胞群体的流行证明了针对癌症治疗的高度特异性治疗选择的必要性。这些抗癌药物的耐药性极大地阻碍了癌症的成功治疗。考虑到这种持续的情况,人们推测开发针对疟疾和癌症的新型化合物。沿着同样的思路,我们使用多步反应途径合成了吡唑丙烯酸基恶二唑和酰胺衍生物(6a-x;6a'-h')。裂殖体成熟抑制试验用于确定抗疟潜力。化合物 6v 成为针对疟原虫蛋白酶 2 酶的最有效抗疟剂。使用磺基罗丹明 B 测定法进行抗癌活性。化合物 6b'和 6g'对所有测试的细胞系均表现出有希望的结果。此外,显微镜观察清楚地表明形成了凋亡小体、染色质浓缩、细胞收缩和泡形成。通过分子对接研究验证了结果。从获得的结果可以看出,环化(恶二唑)有利于抗疟活性,而非环化化合物(酰胺)则成为更好的抗癌药物。